Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Metabolic Effects of Antiretroviral Drugs in Healthy Volunteers
NCT05652478Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dolutegravir, tenofovir alafenamide and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Change in plasma metabolites at 4 weeks. Started Sep 2026; status: recruiting.
02
Drugs
dolutegravirtenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05652478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652478.